Jazz Pharmaceuticals (JAZZ) Free Cash Flow (2010 - 2026)

Jazz Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 20.41% year-over-year to $331.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 21.87% YoY), while the FY2025 annual figure was $1.3 billion, down 7.08% from the prior year.
• Free Cash Flow was $331.0 million for Q1 2026 at Jazz Pharmaceuticals, down from $345.8 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $1.3 billion in Q3 2025 to a low of -$755.3 million in Q2 2025.
• Historically, Free Cash Flow has averaged $313.8 million across 5 years, with a median of $324.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow soared 742.36% in 2022, then sank 332.93% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $332.6 million in 2022, then plunged by 52.72% to $157.2 million in 2023, then jumped by 153.49% to $398.6 million in 2024, then declined by 13.24% to $345.8 million in 2025, then slipped by 4.28% to $331.0 million in 2026.
• The last three Free Cash Flow figures came in at $331.0 million (Q1 2026), $345.8 million (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.